Press Release: Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia
Industry News
Blog|Jul 7 2025
Meet the Community: Megan Ploch
Community
News|Jul 3 2025
June/July 2025 – Advocacy Newsletter
Advocacy
News|Jun 30 2025
Press Release: Muscular Dystrophy Association and Friedreich’s Ataxia Research Alliance Announce New Collaborative Grant to Study Cardiac Fibrosis in Friedreich’s Ataxia
FARA News
Blog|Jun 30 2025
Meet the Community: Kailey Newcity
Community
Blog|Jun 23 2025
2025 Cure FA Soirée Recap
Events
News|Jun 23 2025
Press Release: Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program
Industry News
News|Jun 18 2025
Press Release and Community Statement: Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
Industry News
Blog|Jun 16 2025
Meet the Community: Mark Kuchmas
Community
Blog|Jun 9 2025
Meet the Community: Luciana Grasiele Nogueira
Community
News|Jun 5 2025
Webinar Recording: Biogen May 2025 Update
FARA News | Industry News
News|Jun 5 2025
Webinar Recording: Lexeo Therapeutics May 2025 Update